Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakır, Turkey.
Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.
Future Oncol. 2021 May;17(13):1611-1624. doi: 10.2217/fon-2020-1032. Epub 2021 Feb 26.
To assess the efficacy and tolerability of the first-line treatment options for hormone-refractory prostate cancer patients with visceral metastases. The records of 191 patients diagnosed with hormone-refractory prostate cancer with visceral metastases were analyzed retrospectively. Docetaxel was administered to 61.2% (n = 117), abiraterone to 14.2% (n = 27) and enzalutamide to 9.4% (n = 18) as the first-line treatment. The median survival of the patients receiving docetaxel, abiraterone and enzalutamide as the first-line treatment during the hormone-refractory period was 15 (95% Cl: 12.9-17) months, 6 (95% Cl: 1.8-10.1) months and 11 (95% Cl: 0.9-23.1) months (p = 0.038), respectively. The present study established a statistically significant difference in favor of docetaxel in terms of overall survival and progression-free survival.
评估有内脏转移的激素难治性前列腺癌患者一线治疗方案的疗效和耐受性。回顾性分析了 191 例诊断为有内脏转移的激素难治性前列腺癌患者的记录。一线治疗中，61.2%（n=117）的患者接受多西他赛治疗，14.2%（n=27）的患者接受阿比特龙治疗，9.4%（n=18）的患者接受恩扎卢胺治疗。接受多西他赛、阿比特龙和恩扎卢胺作为激素难治期一线治疗的患者中位生存期分别为 15（95%Cl：12.9-17）个月、6（95%Cl：1.8-10.1）个月和 11（95%Cl：0.9-23.1）个月（p=0.038）。本研究在总生存期和无进展生存期方面均显示多西他赛具有统计学意义上的优势。
